Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

67 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Eculizumab discontinuation in children and adults with atypical hemolytic-uremic syndrome: a prospective multicenter study.
Fakhouri F, Fila M, Hummel A, Ribes D, Sellier-Leclerc AL, Ville S, Pouteil-Noble C, Coindre JP, Le Quintrec M, Rondeau E, Boyer O, Provôt F, Djeddi D, Hanf W, Delmas Y, Louillet F, Lahoche A, Favre G, Châtelet V, Launay EA, Presne C, Zaloszyc A, Caillard S, Bally S, Raimbourg Q, Tricot L, Mousson C, Le Thuaut A, Loirat C, Frémeaux-Bacchi V. Fakhouri F, et al. Among authors: chatelet v. Blood. 2021 May 6;137(18):2438-2449. doi: 10.1182/blood.2020009280. Blood. 2021. PMID: 33270832 Free article. Clinical Trial.
Eculizumab for atypical hemolytic uremic syndrome recurrence in renal transplantation.
Zuber J, Le Quintrec M, Krid S, Bertoye C, Gueutin V, Lahoche A, Heyne N, Ardissino G, Chatelet V, Noël LH, Hourmant M, Niaudet P, Frémeaux-Bacchi V, Rondeau E, Legendre C, Loirat C; French Study Group for Atypical HUS. Zuber J, et al. Among authors: chatelet v. Am J Transplant. 2012 Dec;12(12):3337-54. doi: 10.1111/j.1600-6143.2012.04252.x. Epub 2012 Sep 7. Am J Transplant. 2012. PMID: 22958221 Free article.
Complement genes strongly predict recurrence and graft outcome in adult renal transplant recipients with atypical hemolytic and uremic syndrome.
Le Quintrec M, Zuber J, Moulin B, Kamar N, Jablonski M, Lionet A, Chatelet V, Mousson C, Mourad G, Bridoux F, Cassuto E, Loirat C, Rondeau E, Delahousse M, Frémeaux-Bacchi V. Le Quintrec M, et al. Among authors: chatelet v. Am J Transplant. 2013 Mar;13(3):663-75. doi: 10.1111/ajt.12077. Epub 2013 Jan 28. Am J Transplant. 2013. PMID: 23356914 Free article.
Insights from the use in clinical practice of eculizumab in adult patients with atypical hemolytic uremic syndrome affecting the native kidneys: an analysis of 19 cases.
Fakhouri F, Delmas Y, Provot F, Barbet C, Karras A, Makdassi R, Courivaud C, Rifard K, Servais A, Allard C, Besson V, Cousin M, Châtelet V, Goujon JM, Coindre JP, Laurent G, Loirat C, Frémeaux-Bacchi V. Fakhouri F, et al. Among authors: chatelet v. Am J Kidney Dis. 2014 Jan;63(1):40-8. doi: 10.1053/j.ajkd.2013.07.011. Epub 2013 Sep 8. Am J Kidney Dis. 2014. PMID: 24021908
One-year Results of the Effects of Rituximab on Acute Antibody-Mediated Rejection in Renal Transplantation: RITUX ERAH, a Multicenter Double-blind Randomized Placebo-controlled Trial.
Sautenet B, Blancho G, Büchler M, Morelon E, Toupance O, Barrou B, Ducloux D, Chatelet V, Moulin B, Freguin C, Hazzan M, Lang P, Legendre C, Merville P, Mourad G, Mousson C, Pouteil-Noble C, Purgus R, Rerolle JP, Sayegh J, Westeel PF, Zaoui P, Boivin H, Le Gouge A, Lebranchu Y. Sautenet B, et al. Among authors: chatelet v. Transplantation. 2016 Feb;100(2):391-9. doi: 10.1097/TP.0000000000000958. Transplantation. 2016. PMID: 26555944 Clinical Trial.
Pathogenic Variants in Complement Genes and Risk of Atypical Hemolytic Uremic Syndrome Relapse after Eculizumab Discontinuation.
Fakhouri F, Fila M, Provôt F, Delmas Y, Barbet C, Châtelet V, Rafat C, Cailliez M, Hogan J, Servais A, Karras A, Makdassi R, Louillet F, Coindre JP, Rondeau E, Loirat C, Frémeaux-Bacchi V. Fakhouri F, et al. Among authors: chatelet v. Clin J Am Soc Nephrol. 2017 Jan 6;12(1):50-59. doi: 10.2215/CJN.06440616. Epub 2016 Oct 31. Clin J Am Soc Nephrol. 2017. PMID: 27799617 Free PMC article.
Prognostic Value of the Persistence of C1q-Binding Anti-HLA Antibodies in Acute Antibody-Mediated Rejection in Kidney Transplantation.
Bailly E, Anglicheau D, Blancho G, Gatault P, Vuiblet V, Chatelet V, Morelon E, Malvezzi P, Parissiadis A, Tourret J, Guidicelli G, Sayegh J, Mousson C, Grimbert P, Top I, Le Quintrec M, Purgus R, Westeel PF, Proust B, Chabot V, Lebranchu Y, Dehaut F, Büchler M. Bailly E, et al. Among authors: chatelet v. Transplantation. 2018 Apr;102(4):688-698. doi: 10.1097/TP.0000000000002002. Transplantation. 2018. PMID: 29135832 Clinical Trial.
Eculizumab reversed severe distal ischemic syndrome and glomerulonephritis with isolated C3 deposits associated with anti-factor H autoantibodies: a case report.
Deshayes S, Martin Silva N, Chatelet V, Chantepie S, Le Quintrec M, Comoz F, Bridoux F, Dragon-Durey MA, Aouba A. Deshayes S, et al. Among authors: chatelet v. Clin Rheumatol. 2018 Apr;37(4):1119-1122. doi: 10.1007/s10067-018-4058-6. Epub 2018 Mar 7. Clin Rheumatol. 2018. PMID: 29516279 Review.
67 results